“We anticipate manufacturers’ focus on Asia’s obesity market will grow, particularly in China and Japan, where penetration is low and innovation continues to emerge,” says Morgan Stanley Equity Analyst Thibault Boutherin. Costa declined to identify countries or banks that may have received any drug money, saying that would be inappropriate because his office is supposed to address the problem, not apportion blame. Cocaine produced in Colombia and Bolivia has increasingly been shipped via West Africa (especially in Nigeria, Cape Verde, Guinea-Bissau, Cameroon, Mali, Benin, Togo, and Ghana).31 The money is often laundered in countries such as Nigeria, Ghana, and Senegal.
Which Distribution Channel Led The Market In 2024?
Also, this kind of consistent innovation impels demand for branded drugs, as patients are looking for novel treatments for different diseases. Patients prefer branded drugs because of their recognized quality, efficacy, or familiarity with the brand names. Advancements in biologics, personalized medicine, and RNAi-based therapeutics are enhancing treatment outcomes.
Why Is Corticosteroid Treatment Necessary In The Management Of Respiratory Disorders?
Across the world, there is a major growth in chronic diseases like cardiovascular issues, diabetes, obesity, and cancer, which are driving the growth of the drugs market. Further, the growing awareness about health and hygiene, along with increasing capital, is impacting demand for superior hospitals, drugs, and pharmacy offerings. The Middle East and Africa pharmaceutical market is expanding due to improving healthcare infrastructure and a rising burden of chronic diseases. Saudi Arabia is a prominent market, supported by healthcare modernization initiatives and government investments in biopharmaceutical research. Efforts to enhance patient access and the demand for advanced therapies contribute to market growth.
Pharmaceutical Market Insights
Brick-and-mortar chains are responding by integrating same-day delivery and store pickup options to preserve foot traffic. As these models coexist, logistics efficiency and user-centric digital tooling will influence share shifts across the generic drugs market. High-revenue monoclonal antibodies such as ustekinumab and vedolizumab begin losing exclusivity in 2025, unlocking a USD 25 billion oncology and immunology biosimilar opportunity by 2029.
- Primarily, merging challenges in the drugs market, the increasing spending on both branded and generic drugs, particularly specialty drugs and biologics, generated complexity for many patients, specifically in developing countries, to procure essential treatments.
- Furthermore, funding supports generic drug manufacturers in expanding their market reach and distribution networks.
- The generic drugs market size for biosimilars in oncology alone is projected to surpass USD 25 billion by 2029, underscoring the strategic imperative to scale analytical comparability platforms.
- When people smoke, they inhale harmful substances into their lungs, causing damage over time.
- The presence of notable generic drug manufacturers in Europe, such as Teva Pharmaceutical Industries Ltd., Mylan NV, and Novartis International AG, favors the growth of the generic drugs market.
The India Drugs Market Trends
Additionally, drugs can be delivered through the injection route even when the patient is unconscious. The FDA is responsible for reviewing and approving generic drugs to ensure their safety, efficacy, and quality. When a generic drug receives first-time approval from the FDA, it signifies that the generic version has met all the necessary requirements to be marketed and sold in the United States.
US Over The Counter (OTC) Drugs Market Growth Factors
Europe retains a robust footprint built on reference pricing, tendering, and high biosimilar acceptance. Market share in Germany and the Nordics reaches near-saturation, yet growth stems from therapy class switches as high-cost biologics lose exclusivity. The European Commission’s strategy to relocate essential medicine production within the bloc could redefine supply chains, deliver cost-plus contracts to reliable producers, and lessen exposure to single-country disruptions. Parallel trade and frequent price audits continue to limit margin headroom, requiring firms to exploit economies of scope and continuous-manufacturing technologies. Data collection and base year analysis are done using data collection modules with large sample sizes.
Access 74+ Detailed Reports Featuring Market Insights, Trends, Forecasts, & Competitive Analysis Across Sectors:
- The orphan segment is anticipated to grow at a comparatively higher CAGR over the forecast period.
- The massive revenue potential unlocked by patent expiries acts as a powerful magnet, attracting numerous competitors into the same space.
- An agile pivot to inhalables therefore offers a hedge against margin compression in crowded injectable lines while broadening therapeutic reach across the generic drugs market.
- Consumption of illegal drugs is widespread globally, and it remains very difficult for local authorities to reduce the rates of drug consumption.
Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope. Other key areas include CNS disorders, immunosuppressants, vaccines, and autoimmune therapies. Additionally, some of the key industry players are focusing on the development of orphan drugs for the treatment of several rare disorders. In this market, the increasing R&D investments by prominent companies for the development of new drugs are one of the main key trends. Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology and healthcare services. Prescription drugs require a prescription from a healthcare professional, while over-the-counter drugs can be purchased directly from a pharmacy or store without a prescription.
On the other hand, online pharmacies are anticipated to attain significant growth rate from 2022 to 2030. Rising trend of online ordering and increasing e-commerce websites are the leading factors that are boosting the prescription drugs market value. As per the statistics released by the Association for Accessible Medicines, in 2016, nearly 3.9 billion generic prescriptions were dispensed. Generics account for 89% of the prescription dispensed but only 26% of total drug costs specifically in the US. The general acceptance of generic substitution has increased the efficiency of the prescription drug market. The utility of generic drugs results in a higher level of adherence and has decreased healthcare costs while improving outcomes.
The region’s advanced healthcare infrastructure and strong focus on research and development have facilitated the introduction of innovative treatments. These combined factors have firmly positioned North America as the leading market for ophthalmic drugs. Key factors that are driving the market growth include the rising prevalence of chronic diseases, high utilization of prescription drugs, and the increasing elderly population in the country. Pipeline momentum is strongest in oncology and immunology therapeutics, with companies positioning to secure the next tranche of losses of exclusivity through 2027. The generic drugs market size for biosimilars in oncology alone is projected to surpass USD 25 billion by 2029, underscoring the strategic imperative to scale analytical comparability platforms.
Missing Comfort Of Reading Report In Your Local Language? Find Your Preferred Language :
Additionally, government initiatives promoting generic drug usageand expanding pharmaceutical companies in emerging markets contribute toindustry growth. With continuous advancements in manufacturing and regulatoryapprovals, the generic drugs market is set for sustained expansion. The generic drugs market is segmented by molecule complexity, route of administration, therapeutic area, distribution channel, and geography.
NIDA also supports the National Drug Early Warning System (NDEWS) to track emerging substances and their impact on drug-related emergency calls. NIDA conducts research on specific emerging drugs through its Designer Drug Research Unit and through support for the National Drug Early Warning System (NDEWS), which detects early signals of potential drug epidemics. NDEWS uses traditional surveillance methods like drug-related emergency calls, and newer tools like wastewater analysis and tracking of social media trends. Moreover, the rapid adoption of automation technologies, such as robots, automated dispensing cabinets, and packaging systems, is driving the segment’s growth.
Generic Drugs Market Analysis By Mordor Intelligence
When examining small molecule drugs, 57 percent had at least 2manufacturers, whereas only 19 percent of biological products had at least 2manufacturers. However, once we narrowed the market to only specialty drugsand the highest priced drugs, then competition in both markets erodedsubstantially. Among specialty drugs, 63 percent of small molecule drugs and87 percent of biological products had only a single manufacturer. Finally,when examining only the highest priced drugs (i.e., those in the top 10percent of spending per prescription), we found that 11 percent of smallmolecule drugs and 0 percent of biological products had at least 2manufacturers.
Making sure that products are safe for consumers is a continuous problem since certain components may have negative effects or interact with other treatments. The rate of penetration of obesity drugs is estimated to jump from about 1% currently to 10% of the obese population in the next 10 years, reaching a total market of $70 billion. “We believe we are now at an inflection point for the broadening of obesity drugs’ use, which will extend beyond the U.S. to larger numbers of patients globally,” says Morgan Stanley Equity Analyst Terence Flynn. The Institute studies or supports research on changes in the lab-made drug supply and how these emerging substances work in the brain, as well as their health effects and potential as therapeutic treatments.
